Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass Spectrometry

The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed Beta-2 Microglobulin through Distinct Binding Sites

Biochemistry.

Merkle PS, Irving M, Hongjian S, Ferber M, Jørgensen TJD, Scholten K, Luescher IF, Coukos G, Zoete V, Cuendet MA, Michielin O, Rand KD

doi: 10.1021/

Lymphoma

The CAR T Cell Story

healthbook TIMES Oncology Hematology

Russkamp N., Zenz T.

doi: 10.36000/hbT.OH.2019.01.001

Leukemia

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

J Clin Oncol.

Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ

doi: 10.1200/JCO.19.03279.

Lymphoma

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

N Engl J Med.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH

doi: 10.1056/NEJMoa1708566.

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses

PLoS One.

Spodzieja M, Lach S, Iwaszkiewicz J, Cesson V, Kalejta K, Olive D, Michielin O, Speiser DE, Zoete V, Derré L, Rodziewicz-Motowidło S

doi: 10.1371/

Folate Receptor α: A New Target for an Old Enemy?

★ 3 Recommended by Alexander Meisel, Faculty Member

1Brustzentrum St.Gallen, Kantonsspital St.Gallen, St.Gallen, Switzerland

Leukemia

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody

Blood

Augsberger C, Hänel G, Xu W, Pulko V, Hanisch LJ, Augustin A, Challier J, Hunt K, Vick B, Rovatti PE, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz AC, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin NP, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M

doi: 10.1182/blood.2020010477

COMMENTED

Lymphoma

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

★ 1 Recommended by Prof. Dr Stephan Bodis, Faculty Member

★ 2 Recommended and commented by Prof. Dr Christoph Renner, Faculty Member

doi: 10.1056/NEJMoa1914347.

Leukemia

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

J Clin Oncol.

Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG

doi: 10.1200/JCO.2017.72.8519.

Related content

The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed Beta-2 Microglobulin through Distinct Binding Sites

The CAR T Cell Story

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses

Folate Receptor α: A New Target for an Old Enemy?

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib